SCHEMBL3756655

SCHEMBL3756655

Cc1c(-c2ccccc2)[c]ncc1C(=O)N1CCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.48
TSHR P16473 1/20 0.47
RECQL P46063 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.43
KMT2A Q03164 5/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 3/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C9 P11712 1/20 0.42
MEN1 O00255 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 1/20 0.41
ATM Q13315 1/20 0.40
PDE10A Q9Y233 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758808 0.97 TSHR (0.50) HTTTSHRRECQLSMN1; SMN2GAA
SCHEMBL3765086 0.96 TSHR (0.49) HTTTSHRRECQLSMN1; SMN2GAA
SCHEMBL3756490 0.89 SIGMAR1 (0.47) KMT2ALMNA
SCHEMBL3758917 0.81 CNR1 (0.46) HTTKMT2ALMNAMEN1POLB
SCHEMBL3760380 0.80 TSHR (0.50) HTTTSHRRECQLSMN1; SMN2KMT2A
SCHEMBL3760647 0.77 TSHR (0.54) TSHRRECQLSMN1; SMN2KMT2AHPGD
SCHEMBL3764989 0.76 SMN1; SMN2 (0.44) HTTTSHRRECQLSMN1; SMN2GAA
SCHEMBL3760043 0.76 SMN1; SMN2 (0.44) HTTTSHRRECQLSMN1; SMN2KMT2A
SCHEMBL3769092 0.76 TSHR (0.52) HTTTSHRRECQLSMN1; SMN2KMT2A
SCHEMBL3760094 0.75 AXL (0.45) TSHRSMN1; SMN2GAAKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA HTT 1234/4885TSHR 1753/4885RECQL 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.